Tag: Lipoglycopeptides

As a vital class of "last-resort" antibiotics, glycopeptides are used to treat some of the most serious and drug-resistant bacterial infections, particularly those caused by Gram-positive organisms. This class of drugs, which includes vancomycin, dalbavancin, and others, is a crucial line of defense in modern medicine.

Since the discovery of vancomycin in 1953, glycopeptide antibiotics have become a critical line of defense against serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). These complex molecules are a last resort for many drug-resistant pathogens.

The emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) has posed a significant public health concern since the 1960s [1.2.4]. This has led to the pivotal question for clinicians: in the face of resistance and treatment challenges, **what antibiotic is better than vancomycin?**